Zoliflodacin
Uncomplicated gonorrhea, especially resistant Neisseria gonorrhoeae
- CAS No.
- 1620458-09-4
- Indication Class
- Anti-infectives
- Patent Expiry
- To be assessed
- Therapeutic Area
- Anti-infective / Resistant Bacteria
- Labeled Purity
- 98%+
- Registration Readiness
- GMP/DMF
- Commercialization Tier
- API (Commercialized)
- Linked Intermediates
- Confirm per inquiry
Key Intermediates for This API
Order: listed intermediates that accept enquiries first; fragments shared across several APIs rank higherNo intermediate entries are on file for this API yet. You can still enquire by CAS number — we will route it to the supply side for manual sourcing.
Listing Logic · Why It's Worth Listing
An oral single-dose agent with a wholly new mechanism against antimicrobial-resistant gonorrhea, a WHO-priority AMR direction with clear public-health procurement demand.
Anti-infective / Resistant Bacteria · Marketed; available for immediate sourcing
GMP/DMF-ready; supports regulatory filing and audit in target markets
Intermediates confirmed per inquiry
Product Description
Zoliflodacin is a groundbreaking, first-in-class oral antibiotic specifically developed to address the global threat of antimicrobial-resistant gonorrhea. It received U.S. Food and Drug Administration (FDA) approval on December 11, 2025, for the treatment of uncomplicated urogenital gonorrhea caused by Neisseria gonorrhoeae in adults and pediatric patients 12 years of age and older weighing at least 35 kg.
Supply source: Unibest · Zoliflodacin, sourced, vetted and delivered by Unibest. Therapeutic area, indication and listing rationale are qualitative summaries based on public drug knowledge for business reference; actual registration availability and quality specifications are subject to DMF/GMP documentation and the technical agreement confirmed at order.